Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736260 | 0.93 | SIGMAR1 (0.52) | SIGMAR1OPRM1LMNACA12CA9 | |
| SCHEMBL737590 | 0.90 | SIGMAR1 (0.55) | SIGMAR1OPRM1LMNAMMP13 | |
| SCHEMBL737490 | 0.90 | SIGMAR1 (0.58) | SIGMAR1OPRM1MAPTMAPK1TSHR | |
| SCHEMBL736248 | 0.89 | SIGMAR1 (0.48) | SIGMAR1OPRM1LMNACA12CA9 | |
| SCHEMBL738666 | 0.86 | SIGMAR1 (0.59) | SIGMAR1OPRM1LMNACA12CA9 | |
| SCHEMBL737195 | 0.86 | SIGMAR1 (0.44) | SIGMAR1OPRM1LMNACA12CA9 | |
| SCHEMBL738556 | 0.85 | SIGMAR1 (0.49) | SIGMAR1OPRM1LMNACA12CA9 | |
| SCHEMBL737605 | 0.84 | SIGMAR1 (0.46) | SIGMAR1OPRM1MAPTL3MBTL1KDM4E | |
| SCHEMBL737239 | 0.84 | SIGMAR1 (0.44) | SIGMAR1OPRM1LMNACA12CA9 | |
| SCHEMBL737024 | 0.83 | SIGMAR1 (0.43) | SIGMAR1OPRM1LMNACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | SIGMAR1 11/4885OPRM1 15/4885LMNA 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.